512 related articles for article (PubMed ID: 21548727)
1. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
Devrim B; Bozkır A; Canefe K
Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
[TBL] [Abstract][Full Text] [Related]
2. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2 : I. Effects of some formulation parameters on microparticle characteristics.
Devrim B; Bozkir A; Canefe K
J Microencapsul; 2011; 28(6):582-94. PubMed ID: 21827360
[TBL] [Abstract][Full Text] [Related]
4. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Ohashi K; Kabasawa T; Ozeki T; Okada H
J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
[TBL] [Abstract][Full Text] [Related]
5. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
6. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
[TBL] [Abstract][Full Text] [Related]
7. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery.
Giovagnoli S; Blasi P; Schoubben A; Rossi C; Ricci M
Int J Pharm; 2007 Mar; 333(1-2):103-11. PubMed ID: 17079101
[TBL] [Abstract][Full Text] [Related]
8. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
9. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles.
Wang Y; Kho K; Cheow WS; Hadinoto K
Int J Pharm; 2012 Mar; 424(1-2):98-106. PubMed ID: 22226876
[TBL] [Abstract][Full Text] [Related]
10. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
Thomas C; Gupta V; Ahsan F
Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
12. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery.
Li X; Guo Q; Zheng X; Kong X; Shi S; Chen L; Zhao X; Wei Y; Qian Z
Drug Deliv; 2009 Apr; 16(3):160-6. PubMed ID: 19514976
[TBL] [Abstract][Full Text] [Related]
13. Simple and scalable method for peptide inhalable powder production.
Schoubben A; Blasi P; Giovagnoli S; Ricci M; Rossi C
Eur J Pharm Sci; 2010 Jan; 39(1-3):53-8. PubMed ID: 19879945
[TBL] [Abstract][Full Text] [Related]
14. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model.
Oh YJ; Lee J; Seo JY; Rhim T; Kim SH; Yoon HJ; Lee KY
J Control Release; 2011 Feb; 150(1):56-62. PubMed ID: 21070826
[TBL] [Abstract][Full Text] [Related]
15. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
16. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery.
Doan TV; Couet W; Olivier JC
Int J Pharm; 2011 Jul; 414(1-2):112-7. PubMed ID: 21596123
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
18. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
Chaw CS; Yang YY; Lim IJ; Phan TT
J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
[TBL] [Abstract][Full Text] [Related]
19. Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.
Rattanupatam T; Srichana T
Drug Deliv; 2014 Sep; 21(6):397-405. PubMed ID: 24401124
[TBL] [Abstract][Full Text] [Related]
20. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs.
Ungaro F; De Rosa G; Miro A; Quaglia F; La Rotonda MI
Eur J Pharm Sci; 2006 Aug; 28(5):423-32. PubMed ID: 16806857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
